Barrington Research reaffirmed their outperform rating on shares of HealthEquity (NASDAQ:HQY – Free Report) in a research report report published on Friday, Benzinga reports. They currently have a $105.00 target price on the stock.
Several other analysts have also recently issued reports on HQY. Wells Fargo & Company boosted their price objective on shares of HealthEquity from $107.00 to $110.00 and gave the company an overweight rating in a research note on Thursday, June 20th. JMP Securities reissued a market outperform rating and set a $105.00 price objective on shares of HealthEquity in a research note on Wednesday, September 4th. Royal Bank of Canada reissued an outperform rating and set a $92.00 price objective on shares of HealthEquity in a research note on Wednesday, September 4th. Deutsche Bank Aktiengesellschaft lifted their target price on shares of HealthEquity from $102.00 to $103.00 and gave the company a buy rating in a report on Wednesday, September 4th. Finally, Raymond James lifted their target price on shares of HealthEquity from $100.00 to $105.00 and gave the company an outperform rating in a report on Friday, June 7th. One research analyst has rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat.com, the company has an average rating of Moderate Buy and an average price target of $103.83.
Read Our Latest Stock Report on HQY
HealthEquity Stock Down 0.4 %
Insider Buying and Selling
In related news, Director Frank Corvino sold 7,705 shares of the firm’s stock in a transaction that occurred on Monday, July 8th. The shares were sold at an average price of $81.89, for a total transaction of $630,962.45. Following the completion of the sale, the director now directly owns 6,070 shares in the company, valued at $497,072.30. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In related news, Director Frank Corvino sold 7,705 shares of the firm’s stock in a transaction that occurred on Monday, July 8th. The shares were sold at an average price of $81.89, for a total transaction of $630,962.45. Following the completion of the sale, the director now directly owns 6,070 shares in the company, valued at $497,072.30. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Vice Chairman Stephen Neeleman sold 35,000 shares of the firm’s stock in a transaction that occurred on Thursday, July 25th. The stock was sold at an average price of $79.86, for a total transaction of $2,795,100.00. Following the completion of the transaction, the insider now directly owns 89,769 shares of the company’s stock, valued at approximately $7,168,952.34. The disclosure for this sale can be found here. 2.20% of the stock is currently owned by insiders.
Institutional Investors Weigh In On HealthEquity
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its position in HealthEquity by 1.7% in the 1st quarter. Vanguard Group Inc. now owns 8,768,632 shares of the company’s stock worth $715,783,000 after buying an additional 149,133 shares in the last quarter. Wasatch Advisors LP raised its holdings in shares of HealthEquity by 8.3% during the 1st quarter. Wasatch Advisors LP now owns 7,409,080 shares of the company’s stock valued at $604,803,000 after purchasing an additional 569,249 shares in the last quarter. Motley Fool Asset Management LLC raised its holdings in shares of HealthEquity by 3,001.0% during the 1st quarter. Motley Fool Asset Management LLC now owns 3,762,064 shares of the company’s stock valued at $307,097,000 after purchasing an additional 3,640,748 shares in the last quarter. Clearbridge Investments LLC raised its holdings in shares of HealthEquity by 1.9% during the 2nd quarter. Clearbridge Investments LLC now owns 2,377,204 shares of the company’s stock valued at $204,915,000 after purchasing an additional 43,491 shares in the last quarter. Finally, Mackenzie Financial Corp raised its holdings in shares of HealthEquity by 16.0% during the 2nd quarter. Mackenzie Financial Corp now owns 2,364,521 shares of the company’s stock valued at $203,822,000 after purchasing an additional 325,906 shares in the last quarter. Hedge funds and other institutional investors own 99.55% of the company’s stock.
HealthEquity Company Profile
HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.
Featured Stories
- Five stocks we like better than HealthEquity
- Stock Dividend Cuts Happen Are You Ready?
- The Average 401k Balance by Age Explained
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- 3 Uranium Stocks To Gain as Microsoft Goes Nuclear to Power AI
- Ride Out The Recession With These Dividend KingsĀ
- Biotech Boom Ahead? Key Stocks and ETFs to Watch Now
Receive News & Ratings for HealthEquity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HealthEquity and related companies with MarketBeat.com's FREE daily email newsletter.